β-Blockers are associated with a reduction in COPD exacerbations
Surya P. Bhatt(University of Alabama at Birmingham), Mark T. Dransfield(University of Alabama at Birmingham), Edwin K. Silverman(Brigham and Women's Hospital), James D. Crapo(National Jewish Health), John E. Hokanson(University of Colorado Anschutz Medical Campus), George R. Washko(Brigham and Women's Hospital), Matthew J. Budoff(The Lundquist Institute), Young-il Kim(University of Alabama at Birmingham), J. Michael Wells(University of Alabama at Birmingham), Gregory L. Kinney(Colorado School of Public Health), William C. Bailey(University of Alabama at Birmingham), Hrudaya Nath(University of Alabama at Birmingham)
Cited by 122
Related Papers
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
|American Journal of Respiratory and Critical Care Medicine|2010|1k
An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2010|986
Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
|PLoS ONE|2012|849
Chronic obstructive pulmonary disease
|Nature Reviews Disease Primers|2015|733